這是一項跨國、多中心、前瞻性及回顧性、觀察性、隊列研究，對象為骨髓增殖性腫瘤患者。
適應症：Myeloproliferative Neoplasm、Polycythemia Vera、Essential Thrombocythemia、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis、Primary Myelofibrosis、Primary Myelofibrosis, Prefibrotic Stage、Primary Myelofibrosis, Fibrotic Stage
收案條件
納入條件
- Age ≥ 18 years old at the time of diagnosis of MPN.
- Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
- Polycythaemia vera
- Essential thrombocythemia
- Primary myelofibrosis, pre-fibrotic/early stage
- Primary myelofibrosis, overt fibrotic stage
- Post-polycythaemia vera myelofibrosis
- Post-essential thrombocythaemia myelofibrosis
- MPN-unclassifiable
- All subjects need to provide informed consent.
排除條件
- A subject will not be eligible if he/she meets any of the following criteria:
- \. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。